Compare Abbott Laboratories (ABT) vs Arko Corp. (ARKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Arko Corp. — how do they compare? Abbott Laboratories trades at $95.62 (market cap $166.94B), while Arko Corp. trades at $8.08 (market cap $880.66M). The key difference: Abbott Laboratories is far larger — about 189.6× Arko Corp.'s market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | ARKO | |
|---|---|---|
Market Cap | $166.94B | $880.66M |
Sector | Health | Consumer Cyclical |
52-Week High | $136.62 | $8.64 |
52-Week Low | $82.57 | $3.82 |
Enterprise Value | $193.69B | $3.05B |
Dividend Yield | 2.63% | 1.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
ARKO trades at $7.85, down 2.36% today, with a bullish technical signal from moving averages. The company reported Q1 2026 earnings of -$0.07 per share, beating expectations, but revenue has declined from $9.4B in 2023 to $7.6B in 2025. Net income margin remains thin at 0.38%, while the P/E ratio of 39.75 suggests high earnings expectations relative to current profits. Recent news highlights ARKO as a defensive pick amid inflation concerns.
The outlook is mixed: positive technical momentum and defensive stock characteristics offer upside, but weak revenue growth and low profitability pose risks. All covering analysts rate it Hold, indicating caution. Investment appeal hinges on margin improvement and stable cash flow to support dividends, though high debt and economic sensitivity remain concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Arko Corp.
ARKO Corp operates as a holding company. The company, through its subsidiaries, owns and operates convenience stores in the United States. Some of its regional store brands include Stop, Admiral, Apple Market, BreadBox, E-Z Mart, fas mart, Li'l Cricket, and Next Door Store. Its retail store offers hot food service, beverages, cigarettes & other tobacco products, candy, salty snacks, grocery, beer, and general merchandise. ARKO operates in three segments: Retail, Wholesale, and GPM Petroleum. The company derives the majority of its revenue from retail and wholesale distribution of fuel.
Read more on ARKO →
